Sam-A Pharm Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Sam-A Pharm has been growing earnings at an average annual rate of 40.2%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 12.5% per year. Sam-A Pharm's return on equity is 11.6%, and it has net margins of 24.1%.
Anahtar bilgiler
40.2%
Kazanç büyüme oranı
40.2%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 11.3% |
| Gelir büyüme oranı | 12.5% |
| Özkaynak getirisi | 11.6% |
| Net Marj | 24.1% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% Dive
Aug 25
Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%
Jul 11Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?
Jun 21Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The Market
May 25Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its Dividend
Apr 08Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?
Mar 04How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 28
Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend Date
Dec 24Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?
Dec 07Gelir ve Gider Dağılımı
Sam-A Pharm nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 102,550 | 24,744 | 30,431 | 5,637 |
| 31 Mar 24 | 102,511 | 23,936 | 30,249 | 6,105 |
| 31 Dec 23 | 97,211 | 21,374 | 29,592 | 6,398 |
| 30 Sep 23 | 95,931 | 20,338 | 28,622 | 6,431 |
| 30 Jun 23 | 95,324 | 20,387 | 27,750 | 5,441 |
| 31 Mar 23 | 87,159 | 15,531 | 31,390 | 1,451 |
| 31 Dec 22 | 81,700 | 11,912 | 26,661 | 3,771 |
| 30 Sep 22 | 75,479 | 11,029 | 24,036 | 2,977 |
| 30 Jun 22 | 66,172 | 7,520 | 22,587 | 3,258 |
| 31 Mar 22 | 63,638 | 7,000 | 16,024 | 7,600 |
| 31 Dec 21 | 54,666 | 3,392 | 20,814 | 3,829 |
| 30 Sep 21 | 50,907 | 178 | 20,969 | 3,776 |
| 30 Jun 21 | 50,870 | -1,115 | 21,690 | 4,120 |
| 31 Mar 21 | 48,548 | -1,650 | 23,102 | 2,847 |
| 31 Dec 20 | 53,653 | 124 | 22,780 | 3,681 |
| 30 Sep 20 | 59,775 | 3,392 | 22,977 | 4,161 |
| 30 Jun 20 | 64,025 | 5,986 | 25,136 | 4,133 |
| 31 Mar 20 | 70,346 | 9,128 | 25,824 | 4,843 |
| 31 Dec 19 | 71,560 | 10,197 | 26,105 | 5,386 |
| 30 Sep 19 | 70,715 | 9,807 | 27,220 | 5,728 |
| 31 Dec 18 | 66,947 | 8,801 | 26,278 | 4,889 |
Kaliteli Kazançlar: A009300 has high quality earnings.
Büyüyen Kar Marjı: A009300's current net profit margins (24.1%) are higher than last year (21.4%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: A009300's earnings have grown significantly by 40.2% per year over the past 5 years.
Büyüme Hızlandırma: A009300's earnings growth over the past year (21.4%) is below its 5-year average (40.2% per year).
Kazançlar vs. Sektör: A009300 earnings growth over the past year (21.4%) did not outperform the Pharmaceuticals industry 21.9%.
Özkaynak Getirisi
Yüksek ROE: A009300's Return on Equity (11.6%) is considered low.